Pegfilgrastim biosimilar - Jiangsu Hengrui Medicine Co.

Drug Profile

Pegfilgrastim biosimilar - Jiangsu Hengrui Medicine Co.

Alternative Names: HHPG-19K; Pegylated rhG-CSF - Jiangsu Hengrui

Latest Information Update: 11 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Neutropenia

Most Recent Events

  • 06 May 2015 Phase-III development is ongoing in China
  • 22 Oct 2013 Biomarkers information updated
  • 01 Jan 2013 Jiangsu Hengrui Medicine Co. completes a phase III trial in Neutropenia (chemotherapy-induced, prevention) in China (NCT01611051)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top